Education
About Us
Working with TipRanks
Follow Us
Roche Holding AG (RHHVF)
OTHER OTC:RHHVF
RHHVF Stock Chart & Stats
$439.16
-$1.53(-0.53%)
At close: 4:00 PM EST
$439.16
-$1.53(-0.53%)
Day’s Range― - ―
52-Week Range$277.00 - $442.36
Previous CloseN/A
Volume301.00
Average Volume (3M)14.00K
Market Cap
$348.58B
Enterprise Value$232.87B
Total Cash (Recent Filing)$12.03B
Total Debt (Recent Filing)$34.63B
Price to Earnings (P/E)32.0
Beta0.25
Next Earnings
Jan 29, 2026EPS Estimate
10.83Next Dividend Ex-DateN/A
Dividend Yield2.62%
Share Statistics
EPS (TTM)13.85
Shares Outstanding702,562,700
10 Day Avg. Volume3,014
30 Day Avg. Volume13,999
Financial Highlights & Ratios
PEG Ratio-0.88
Price to Book (P/B)6.41
Price to Sales (P/S)3.26
P/FCF Ratio13.50
Enterprise Value/Market Cap0.67
Enterprise Value/Revenue5.00
Enterprise Value/Gross Profit6.80
Enterprise Value/Ebitda18.62
Forecast
1Y Price Target
$411.68Price Target Upside-6.26% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering11
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial ReadoutsAnalyst upgrade to Neutral cites reduced catalyst risk after positive late-stage readouts for fenebrutinib in relapsing multiple sclerosis and giredestrant in the adjuvant setting, raising confidence for broader upcoming trials.
Diabetes Care ExpansionExpansion into continuous glucose monitoring with a differentiated, AI-integrated device linked to an emerging GLP-1 treatment portfolio targets conversion of a large existing diabetes customer base and supports diversified revenue growth.
Diagnostics InnovationA new high-speed genetic sequencing platform combined with a proprietary sensor chip could enable faster, more accurate testing, positioning the diagnostics division to challenge the market leader and drive meaningful growth.
Bears Say
Fenebrutinib Safety And Statistical ClarityLimited information on statistical significance and potential liver toxicity for fenebrutinib maintains safety concerns and increases the risk of trial setbacks or regulatory scrutiny.
Giredestrant First-line UncertaintyUncertainties around endocrine sensitivity for giredestrant in the first-line setting keep trial risk elevated and may limit upside from regulatory or adoption catalysts.
Historical Trial SetbacksPrior high-risk trials that produced negative outcomes contributed to a previous Sell rating, creating lingering investor skepticism that could pressure the stock.
Roche Holding AG News
RHHVF FAQ
What was Roche Holding AG’s price range in the past 12 months?
Roche Holding AG lowest stock price was $277.00 and its highest was $442.36 in the past 12 months.
What is Roche Holding AG’s market cap?
Roche Holding AG’s market cap is $348.58B.
When is Roche Holding AG’s upcoming earnings report date?
Roche Holding AG’s upcoming earnings report date is Jan 29, 2026 which is in 10 days.
How were Roche Holding AG’s earnings last quarter?
Roche Holding AG released its earnings results on Jul 24, 2025. The company reported $13.854 earnings per share for the quarter, beating the consensus estimate of $13.467 by $0.388.
Is Roche Holding AG overvalued?
According to Wall Street analysts Roche Holding AG’s price is currently Overvalued.
Does Roche Holding AG pay dividends?
Roche Holding AG pays a Annually dividend of $10.972 which represents an annual dividend yield of 2.62%. See more information on Roche Holding AG dividends here
What is Roche Holding AG’s EPS estimate?
Roche Holding AG’s EPS estimate is 10.83.
How many shares outstanding does Roche Holding AG have?
Roche Holding AG has 702,562,700 shares outstanding.
What happened to Roche Holding AG’s price movement after its last earnings report?
Roche Holding AG reported an EPS of $13.854 in its last earnings report, beating expectations of $13.467. Following the earnings report the stock price went up 1.338%.
Which hedge fund is a major shareholder of Roche Holding AG?
Currently, no hedge funds are holding shares in RHHVF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, Austria, Netherlands, the United Kingdom, France, Belgium, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation. It also offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases. In addition, the company supplies diagnostic instruments and reagents. The company was founded in 1896 and is headquartered in Basel, Switzerland.
RHHVF Stock 12 Month Forecast
Average Price Target
$411.68
▼(-6.26% Downside)
Technical Analysis
Ownership Overview
―
Insiders
10.57% Mutual Funds
0.04% Other Institutional Investors
76.41% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---